Factors Associated With the Absence of Contraception at Women Seeking a Voluntary Termination of Pregnancy

Factors Associated With the Absence of Contraception at the Time of Unplaned Pregnancy Among Women Seeking a Voluntary Termination of Pregnancy

The study will be offered to all women who are consultant for an abortion plan are seen in consultation at the orthogeny center where the study will be conducted. Of these 700 women, about 10% will not agree to participate in the study and 10% will not meet the inclusion criteria. Thus it's plane to include 560 patients in the study.

Study Overview

• Status: Suspended
• Conditions: Pregnancy, Unwanted

Detailed Description

In 1967, the Neuwirth law allowed women to control their fertility by establishing the right to contraception as a principle. Since then, they have continued to take ownership of the various contraceptive methods, which are regularly renewed.

Contraceptive coverage is important in France as it is estimated that 92% of women of childbearing age use a contraceptive method. The pill remains the most widely used method of contraception (36.5%), ahead of the intrauterine device (25.6%) condoms (15.5%) Several laws have been introduced from 1967 to today to facilitate access to sexual health care: screening for sexually transmitted infections, free provision of emergency contraception to minors, non-prescription delivery of emergency contraception, free consultation at a family planning and education center, voluntary termination of pregnancy 100%, reimbursement of condoms by social security.

Despite all the measures put in place, it is now clear that the number of unplanted pregnancies is decreasing slightly and the number of abortion has remained stable since 2001.

According to the latest literature data, several socio-demographic factors appear to play a role in the rate of use of voluntary termination of pregnancy., including age, socio-cultural level, marital and economic status and ethnic origin. All the more striking, it appears that while voluntary termination of pregnancy are mainly related to contraceptive failures, one third of them involve women who do not have contraception. According to the latest Ined survey, and in accordance with other data from the literature, the factors associated with the absence of contraceptive use are multiple: ignorance about fertility, family or cultural context, cost of contraceptive methods or lack of information related to them.

While these studies have looked at the reasons given by women for the lack of contraception, with little data on the characteristics of these women, particularly socio-demographics and their reproductive history and in particular in the context of unwanted pregnancy. This finding leads us to question the factors associated with the absence of contraception among women in demand of a voluntary termination of pregnancy.

• Study Type: Observational
• Enrollment (Anticipated): 560

Contacts and Locations

Study Locations

• France
  • Villeneuve-Saint-Georges, France
    • CHI Villeneuve St Georges

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

Protocol proposed to woman who wanted a voluntary termination of pregnancy

Description

Inclusion Criteria:

• woman of 18 years of age or older;
• Being French-speaking;
• request for a medical or instrumental voluntary termination of pregnancy
• No opposition to participation in the protocol
• Be affiliated with a social security plan

Exclusion Criteria:

• desired pregnancy

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Association between absence of contraception and socio-demographic factors, characteristics of pregnancy abortion and medical follow-up	Statistically significant association between the absence of contraception in patients consulting for a voluntary termination of pregnancy and socio-demographic factors, characteristics of voluntary termination of pregnancy abortion and characteristics related to medical follow-up	1 hour

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prescription and dispensing of contraception	Prevalence of patients informed about the prescription and dispensing of contraception including emergency contraception	1 hour
Existence of family planning centers	Prevalence of patients informed about the existence of family planning centers	1 hour
Emergency contraception	Prevalence of women who have used emergency contraception	1 hour
Price and reimbursement of condoms	Prevalence of women informed about the price and reimbursement of condoms	1 hour
Knowledge of conception	Estimate the percentage of women who thought they could get pregnant at the time of the intercourse that led to this pregnancy	1 hour
Fertile window	Prevalence of women who use a method to track their fertile window	1 hour
Affection of fertility	Estimate the percentage of women who think that contraception can affect their fertility	1 hour

Collaborators and Investigators

• Sponsor: Centre Hospitalier Intercommunal Creteil

Study record dates

Study Major Dates

• Study Start (Anticipated): November 1, 2022
• Primary Completion (Anticipated): November 1, 2022
• Study Completion (Anticipated): November 1, 2022

Study Registration Dates

• First Submitted: February 11, 2021
• First Submitted That Met QC Criteria: March 31, 2021
• First Posted (Actual): April 2, 2021

Study Record Updates

• Last Update Posted (Actual): February 1, 2022
• Last Update Submitted That Met QC Criteria: January 31, 2022
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Keywords: Contraception; Abortion; Unintended pregnancy; Unplanned pregnancy
• Other Study ID Numbers: NOCONTRAIVG; 2021-A00298-33 (Other Identifier: ID-RCB)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No